Top 10 Arthritis Advances 2006 References
1) Dramatic Surge in Arthritis Predicted
Hootman JM, Helmick CG. Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum 2006;54:226-9.
2) Genetic Links with Rheumatoid Arthritis Identified
Plenge RM, Padyukov L, Remmers EF, et al. Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet. 2005 Dec;77(6):1044-60. Epub 2005 Nov 1.
3) Effectiveness of Biologics in Arthritis
Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54:1063-74.
Weinblatt M, Combe B, Covucci A, et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 2006;54:2807-16.
Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
Schiff M, Keiserman M, Codding C, et al. The efficacy and safety of abatacept or infliximab in RA patients with an inadequate response to MTX: results from a 1-year double-blind, randomized, placebo-controlled trial. American College of Rheumatology Annual Scientific Meeting, November 2006. Presentation Number L43.
Giannini EH, Ruperto N, Prieur AM, et al. Efficacy and safety of abatacept in children and adolescents with active juvenile idiopathic arthritis (JIA): results of double-blind withdrawal phase. American College of Rheumatology Annual Scientific Meeting, November 2006. Presentation Number L2
Lovell DJ, Ruperto N, Jung L, et al. Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis (JRA): 48-week results. American College of Rheumatology Annual Scientific Meeting, November 2006. Presentation Number 659.
4) Importance of Anti-Cyclic Citrullinated Proteins in RA
Kuhn KA, Kulik L, Tomooka B, et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 2006;116:961-73.
Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006;54:38-46.
Klareskog L, Padyukov L, Ronnelid J, et al. Genes, environment and immunity in the development of rheumatoid arthritis. Curr Opin Immunol 2006;18:650-5.
5) Results of Largest Glucosamine–Chondroitin Trial to Date
Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006;354:795-808.
6) High Rate of Relapse in Juvenile Arthritis
Wallace CA, Huang B, Bandeira M, et al. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum 2005;52:3554-62.
7) Immune Cell Involvement in Juvenile Arthritis Better Defined
Jarvis JN, Petty HR, Tang Y, et al. Evidence for chronic, peripheral activation of neutrophils in polyarticular juvenile rheumatoid arthritis. Arthritis Res Ther 2006;8:R154.
8) Help for Seniors Buying Medications
9) New Treatment Possibilities for Systemic Sclerosis
Tashkin DP, Elashoff R, Clements PJ, et al; Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006 Jun 22;354(25):2655-66.
Baroni SS, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med. 2006 Jun 22;354(25):2667-76.
10) Anakinra Effective Against Genetic Form of Juvenile Arthritis
Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-Onset Multisystem Inflammatory Disease responsive to interleukin-1β inhibition. N Engl J Med 2006; 355:581-592.